Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H21ClF2N4O.C4H4O4 |
Molecular Weight | 510.918 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CC1=CN=C(CNCC2(F)CCN(CC2)C(=O)C3=CC=C(F)C(Cl)=C3)N=C1
InChI
InChIKey=GNFUCNCQCSGZJH-WLHGVMLRSA-N
InChI=1S/C19H21ClF2N4O.C4H4O4/c1-13-9-24-17(25-10-13)11-23-12-19(22)4-6-26(7-5-19)18(27)14-2-3-16(21)15(20)8-14;5-3(6)1-2-4(7)8/h2-3,8-10,23H,4-7,11-12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
F-15599 is a novel agonist with high selectivity and efficacy at serotonin 5-HT(1A) receptors. In signal transduction, electrophysiological and neurochemical tests, F-15599 preferentially activates post-synaptic 5-HT(1A)Rs in rat frontal cortex. Such a profile may translate to an improved profile of therapeutic activity for mood disorders. [(18)F]F-15599 is a radiofluorinated agonist presenting interesting characteristics for probing in vitro and in vivo the high-affinity states of the 5-HT(1A) receptors. The Rett Syndrome Research Trust awarded a grant to Neurolixis to advance F-15599 to clinical development.
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
635323-96-5
Created by
admin on Fri Dec 15 20:05:34 GMT 2023 , Edited by admin on Fri Dec 15 20:05:34 GMT 2023
|
PRIMARY | |||
|
119025643
Created by
admin on Fri Dec 15 20:05:34 GMT 2023 , Edited by admin on Fri Dec 15 20:05:34 GMT 2023
|
PRIMARY | |||
|
SUB197522
Created by
admin on Fri Dec 15 20:05:34 GMT 2023 , Edited by admin on Fri Dec 15 20:05:34 GMT 2023
|
PRIMARY | |||
|
7LQS8HJO6C
Created by
admin on Fri Dec 15 20:05:34 GMT 2023 , Edited by admin on Fri Dec 15 20:05:34 GMT 2023
|
PRIMARY | |||
|
100000183188
Created by
admin on Fri Dec 15 20:05:34 GMT 2023 , Edited by admin on Fri Dec 15 20:05:34 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD